Nanomedicine Delivery: does Protein Corona Route to the Target or off Road?

Maiolo, Daniele; Pino, Pablo del; Metrangolo, Pierangelo; Parak, Wolfgang J.; Bombelli, Francesca Baldelli

doi:10.2217/nnm.15.163

Cited by 90 publications

(68 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26][27][28][29] Even though NPs have been found to spontaneously interact with a wide range of different protein molecules once in contact with biofluids, the surface-capture of disease-specific molecules by blood circulating NPs has never been attempted before. 6 The concept of utilizing the nanoparticle protein corona fingerprints for biomarker discovery has been only theoretically proposed and remains experimentally unexplored, 30 with the exception of a recent report by…”

Section: Discussionmentioning

confidence: 99%

A Novel Scavenging Tool for Cancer Biomarker Discovery based on the Blood-Circulating Nanoparticle Protein Corona

Hadjidemetriou

Al-Ahmady

Buggio

et al. 2018

Preprint

View full text Add to dashboard Cite

The prominent discrepancy between the significant investment towards plasma biomarker discovery and the very low number of biomarkers currently in clinical use stresses the need for novel discovery technologies. The discovery of protein biomarkers present in human blood by proteomics is tremendously challenging, owing to the large dynamic concentration range of blood proteins. Here, we describe the use of bloodcirculating lipid-based nanoparticles (NPs) as a scavenging tool to comprehensively analyse the blood circulation proteome. We aimed to exploit the spontaneous interaction of NPs with plasma proteins once injected in the bloodstream, known as 'protein corona' and to facilitate the discovery of previously unreported biomarker molecules for cancer diagnostics. We employed two different tumor models, a subcutaneous melanoma model (B16-F10) and human lung carcinoma xenograft model (A549) and comprehensively compared by mass spectrometry the in vivo protein coronas formed onto clinically used liposomes, intravenously administered in healthy and tumor-bearing mice. The results obtained demonstrated the ability of blood-circulating liposomes to surface-capture and amplify low molecular weight (MW) and low abundant tumor specific proteins (intracellular products of tissue leakage) that could not be detected by plasma analysis, performed in comparison. Most strikingly, the NP (liposomal) corona formed in the xenograft model was found to consist of murine host response proteins, as well as human proteins released from the inoculated and growing human cancer cells. This study offers direct evidence that the in vivo NP protein corona could be deemed as a valuable tool of the blood proteome in experimental disease models to allow the discovery of potential biomarkers.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Scavenging Tool for Cancer Biomarker Discovery based on the Blood-Circulating Nanoparticle Protein Corona

Hadjidemetriou

Al-Ahmady

Buggio

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

“…Besides, the invention of new pharmaceutical technologies such as tumor-on-a-chip models and biomimetic microfluidic systems allow for more deeper evaluation of NP behaviors. 110 Notably, different types of diseases can cause decoration of the NP protein. 111 The changes in plasma protein concentrations, protein structures, and body temperature mediated by different disease states and medical conditions, extensively including breast cancer, diabetes, hypercholesterolemia, rheumatism, fauvism, smoking, hemodialysis, thalassemia, hemophilia A and B, pregnancy, common cold, and hypofibrinogenemia, alter NP-adsorbed protein pattern This new finding also suggests new avenues for creating and designing safe and highly efficient NPs for personalized drug delivery system.…”

Section: Future Perspectivesmentioning

confidence: 99%

Protein corona: a new approach for nanomedicine design

Nguyen¹,

Lee²

2017

IJN

521

343

View full text Add to dashboard Cite

After administration of nanoparticle (NP) into biological fluids, an NP–protein complex is formed, which represents the “true identity” of NP in our body. Hence, protein–NP interaction should be carefully investigated to predict and control the fate of NPs or drug-loaded NPs, including systemic circulation, biodistribution, and bioavailability. In this review, we mainly focus on the formation of protein corona and its potential applications in pharmaceutical sciences such as prediction modeling based on NP-adsorbed proteins, usage of active proteins for modifying NP to achieve toxicity reduction, circulation time enhancement, and targeting effect. Validated correlative models for NP biological responses mainly based on protein corona fingerprints of NPs are more highly accurate than the models solely set up from NP properties. Based on these models, effectiveness as well as the toxicity of NPs can be predicted without in vivo tests, while novel cell receptors could be identified from prominent proteins which play important key roles in the models. The ungoverned protein adsorption onto NPs may have generally negative effects such as rapid clearance from the bloodstream, hindrance of targeting capacity, and induction of toxicity. In contrast, controlling protein adsorption by modifying NPs with diverse functional proteins or tailoring appropriate NPs which favor selective endogenous peptides and proteins will bring promising therapeutic benefits in drug delivery and targeted cancer treatment.

show abstract

“…Intravitreal injection of 10 pmol of GNP were also shown to decrease the choroidal neovascularization by 67.9% without presenting signs of toxicity against RPE cells. Uncontrolled adsorption of proteins on nanoparticles might inhibit their in vivo presumed activity . Jo et al.…”

Section: Gold Nanoparticles For Ophthalmic Therapymentioning

confidence: 99%

Gold nanoparticles in ophthalmology

Masse

Ouellette

Lamoureux

et al. 2018

Medicinal Research Reviews

View full text Add to dashboard Cite

Many research projects are underway to improve the diagnosis and therapy in ophthalmology. Indeed, visual acuity deficits affect 285 million people worldwide and different strategies are being developed to strengthen patient care. One of these strategies is the use of gold nanoparticles (GNP) for their multiple properties and their ability to be used as both diagnosis and therapy tools. This review exhaustively details research developing GNPs for use in ophthalmology. The toxicity of GNPs and their distribution in the eye are described through in vitro and in vivo studies. All publications addressing the pharmacokinetics of GNPs administered in the eye are extensively reviewed. In addition, their use as biosensors or for imaging with optical coherence tomography is illustrated. The future of GNPs for ophthalmic therapy is also discussed. GNPs can be used to deliver genes or drugs through different administration routes. Their antiangiogenic and anti-inflammatory properties are of great interest for different ocular pathologies. Finally, GNPs can be used to improve stereotactic radiosurgery, brachytherapy, and photothermal therapy because of their many properties.

show abstract

Nanomedicine Delivery: does Protein Corona Route to the Target or off Road?

Cited by 90 publications

References 120 publications

A Novel Scavenging Tool for Cancer Biomarker Discovery based on the Blood-Circulating Nanoparticle Protein Corona

A Novel Scavenging Tool for Cancer Biomarker Discovery based on the Blood-Circulating Nanoparticle Protein Corona

Protein corona: a new approach for nanomedicine design

Gold nanoparticles in ophthalmology

Contact Info

Product

Resources

About